Longevity & AgingNew Drug LM11A-31 May Slow Alzheimer's Brain Network Decline
A new drug candidate called LM11A-31, developed by Indiana University and PharmatrophiX, may help protect the brain's communication networks in people with mild-to-moderate Alzheimer's disease. Researchers analyzed brain imaging data from 159 trial participants and found that the drug — especially at the 400 mg dose — improved whole-brain metabolic connectivity and network efficiency, particularly in areas tied to memory. The broader trial of 242 participants also reported a 50% reduction in cognitive decline progression compared to placebo, positive biomarker changes across five categories, and a clean safety profile with no amyloid-related imaging abnormalities. A larger Phase 2b/3 trial is now being planned.
